A detailed history of 683 Capital Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, 683 Capital Management, LLC holds 1,650,000 shares of PHAT stock, worth $17 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares
1,650,000
Previous 1,280,000 28.91%
Holding current value
$17 Million
Previous $11.7 Million 49.95%
% of portfolio
1.49%
Previous 1.19%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.21 - $11.05 $2.3 Million - $4.09 Million
370,000 Added 28.91%
1,650,000 $17.5 Million
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $1.26 Million - $1.93 Million
180,000 Added 16.36%
1,280,000 $11.7 Million
Q3 2023

Nov 14, 2023

SELL
$10.26 - $15.7 $1.92 Million - $2.94 Million
-187,500 Reduced 14.56%
1,100,000 $11.4 Million
Q2 2023

Aug 14, 2023

SELL
$7.28 - $14.32 $276,640 - $544,160
-38,000 Reduced 2.87%
1,287,500 $18.4 Million
Q1 2023

May 15, 2023

SELL
$6.19 - $12.36 $151,655 - $302,820
-24,500 Reduced 1.81%
1,325,500 $9.46 Million
Q4 2022

Feb 14, 2023

SELL
$9.18 - $11.53 $2.88 Million - $3.62 Million
-313,943 Reduced 18.87%
1,350,000 $15.1 Million
Q3 2022

Nov 14, 2022

BUY
$6.46 - $12.11 $1.45 Million - $2.71 Million
223,943 Added 15.55%
1,663,943 $18.4 Million
Q2 2022

Aug 15, 2022

BUY
$6.2 - $15.5 $6.73 Million - $16.8 Million
1,085,000 Added 305.63%
1,440,000 $12.2 Million
Q1 2022

May 16, 2022

BUY
$11.55 - $20.06 $743,877 - $1.29 Million
64,405 Added 22.16%
355,000 $4.83 Million
Q4 2021

Feb 14, 2022

BUY
$17.83 - $33.15 $5.18 Million - $9.63 Million
290,595 New
290,595 $5.72 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $404M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.